litlas
Log inCreate account

Miloslav Beran

Active 1982–2011

76
Papers
18,397
Citations
75
h-index
76
i10-index

Citations

Citations per year for Miloslav Beran1983: 1 citations1984: 1 citations1985: 3 citations1986: 2 citations1987: 8 citations1988: 3 citations1989: 7 citations1990: 6 citations1991: 24 citations1992: 26 citations1993: 12 citations1994: 24 citations1995: 47 citations1996: 47 citations1997: 40 citations1998: 58 citations1999: 78 citations2000: 104 citations2001: 115 citations2002: 218 citations2003: 210 citations2004: 138 citations2005: 179 citations2006: 227 citations2007: 198 citations2008: 165 citations2009: 155 citations2010: 157 citations2011: 147 citations2012: 161 citations2013: 161 citations2014: 144 citations2015: 133 citations2016: 133 citations2017: 106 citations2018: 105 citations2019: 275 citations2020: 289 citations2021: 225 citations2022: 159 citations2023: 93 citations2024: 148 citations2025: 48 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,224 citing papers, 37.4% of this breakdownGermany: 462 citing papers, 7.8% of this breakdownUnited Kingdom: 420 citing papers, 7% of this breakdownItaly: 322 citing papers, 5.4% of this breakdownFrance: 308 citing papers, 5.2% of this breakdownChina: 290 citing papers, 4.9% of this breakdownJapan: 179 citing papers, 3% of this breakdownCanada: 164 citing papers, 2.7% of this breakdownSpain: 160 citing papers, 2.7% of this breakdownNetherlands: 138 citing papers, 2.3% of this breakdownSwitzerland: 131 citing papers, 2.2% of this breakdownAustralia: 106 citing papers, 1.8% of this breakdown
0%37.4%Other 17.6%

Institutions

Fields

  • Medicine75.1%
  • Biochemistry, Genetics and Molecular Biology20.5%
  • Immunology and Microbiology3%
  • Chemistry0.3%
  • Computer Science0.3%
  • Nursing0.2%
  • Other0.6%

Topics

  • Acute Myeloid Leukemia Research14.3%
  • Chronic Myeloid Leukemia Treatments7.8%
  • Chronic Lymphocytic Leukemia Research6.5%
  • Acute Lymphoblastic Leukemia research6.1%
  • Epigenetics and DNA Methylation4.6%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment4.4%
  • Other56.3%

Coauthors

All papers

Open in search
  1. Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

    Authors: Kelly Moran-Crusio, Linsey B. Reavie, Alan H. Shih, Omar Abdel‐Wahab, Delphine Ndiaye‐Lobry, Camille Lobry, María E. Figueroa, Aparna Vasanthakumar, Jay Patel, Xinyang Zhao, Fabiana Perna, Suveg Pandey, Jozef Madžo, Chun‐Xiao Song, Qing Dai, Chuan He, Sherif Ibrahim, Miloslav Beran, Jiří Zavadil, Stephen D. Nimer, Ari Melnick, Lucy A. Godley, Iannis Aifantis, Ross L. Levine - Cancer Cell 2011 cited by 1,311

  2. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

    Authors: Hagop M. Kantarjian, Susan O’Brien, Terry L. Smith, Jörge E. Cortes, Francis J. Giles, Miloslav Beran, Sherry Pierce, Yang O. Huh, Michael Andreeff, Charles Koller, Chul S. Ha, Michael J. Keating, Sharon Murphy, Emil J. Freireich - Journal of Clinical Oncology 2000 cited by 795

  3. Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia

    Authors: Hagop M. Kantarjian, Deborah A. Thomas, Susan O’Brien, Jörge E. Cortes, Francis J. Giles, Sima Jeha, Carlos E. Bueso‐Ramos, Sherry Pierce, Jianqin Shan, Charles Koller, Miloslav Beran, Michael J. Keating, Emil J. Freireich - Cancer 2004 cited by 632

  4. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

    Authors: Farhad Ravandi, Hagop M. Kantarjian, Stefan Faderl, Guillermo Garcia‐Manero, Susan O’Brien, Charles Koller, Sherry Pierce, Mark Brandt, Deborah D. Kennedy, Jörge E. Cortes, Miloslav Beran - Leukemia Research 2009 cited by 124

  5. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

    Authors: Omar Abdel‐Wahab, Ann Mullally, Cyrus V. Hedvat, Guillermo Garcia‐Manero, Jay Patel, Martha Wadleigh, Sébastien Malinge, JinJuan Yao, Outi Kilpivaara, Rukhmi Bhat, Kety Huberman, Sabrena Thomas, Igor Dolgalev, Adriana Heguy, Elisabeth Paietta, Michelle M. Le Beau, Miloslav Beran, Martin S. Tallman, Benjamin L. Ebert, Hagop M. Kantarjian, Richard M. Stone, D. Gary Gilliland, John D. Crispino, Ross L. Levine - Blood 2009 cited by 718

  6. FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitors in a Murine Model of Chronic Myelomonocytic Leukemia

    Authors: Benjamin H. Lee, Zuzana Tóthová, Ross L. Levine, Kristina Anderson, Natalija Buza-Vidas, Dana E. Cullen, Elizabeth McDowell, Jennifer Adelsperger, Stefan Fröhling, Brian J.P. Huntly, Miloslav Beran, Sten Eirik W. Jacobsen, D. Gary Gilliland - Cancer Cell 2007 cited by 225

  7. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

    Authors: Deborah A. Thomas, Susan O’Brien, Jörge E. Cortes, Francis J. Giles, Stefan Faderl, Srđan Verstovšek, Alessandra Ferrajoli, Charles Koller, Miloslav Beran, Sherry Pierce, Chul S. Ha, Fernando Cabanillas, Michael J. Keating, Hagop M. Kantarjian - Blood 2004 cited by 251

  8. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

    Authors: Steven M. Kornblau, Deborah E. Banker, Derek L. Stirewalt, Danny D. Shen, Elizabeth Lemker, Srđan Verstovšek, Zeev Estrov, Stefan Faderl, Jörge E. Cortes, Miloslav Beran, C. Ellen Jackson, Wenjing Chen, Elihu H. Estey, Frederick R. Appelbaum - Blood 2006 cited by 136

  9. Report of an international working group to standardize response criteria for myelodysplastic syndromes.

    Authors: Bruce D. Cheson, John M. Bennett, Hagop M. Kantarjian, António E. Pinto, Charles A. Schiffer, Stephen D. Nimer, Bob Löwenberg, Miloslav Beran, Theo M. de Witte, Richard M. Stone, Moshe Mittelman, Guillermo Sanz, P. Wijermans, Steven D. Gore, Peter L. Greenberg - 2000 cited by 665

  10. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

    Authors: B. Douglas Smith, Mark J. Levis, Miloslav Beran, Francis J. Giles, Hagop M. Kantarjian, Karin D. Berg, Kathleen M. Murphy, Tianna Dauses, Jeffrey Allebach, Donald Small - Blood 2004 cited by 629

  11. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

    Authors: Francesco Onida, Hagop M. Kantarjian, Terry L. Smith, Greg Ball, Michael J. Keating, Elihu H. Estey, Armand B. Glassman, Maher Albitar, Monica Kwari, Miloslav Beran - Blood 2002 cited by 386

  12. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

    Authors: William G. Wierda, Susan O’Brien, Xuemei Wang, Stefan Faderl, Alessandra Ferrajoli, Kim‐Anh Do, Jörge E. Cortes, Deborah A. Thomas, Guillermo Garcia‐Manero, Charles Koller, Miloslav Beran, Francis J. Giles, Farhad Ravandi, Susan Lerner, Hagop M. Kantarjian, Michael J. Keating - Blood 2007 cited by 350

  13. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

    Authors: Elihu H. Estey, Peter F. Thall, Michael Andreeff, Miloslav Beran, Hagop M. Kantarjian, Susan O’Brien, SM Escudier, L. E. Robertson, Charles Koller, Steven M. Kornblau - Journal of Clinical Oncology 1994 cited by 297

  14. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia

    Authors: Razelle Kurzrock, Mordechai Shtalrid, Paolo Romero, William S. Kloetzer, Moshe Talpas, José M. Trujillo, Mark Blick, Miloslav Beran, Jordan U. Gutterman - Nature 1987 cited by 274

  15. Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy

    Authors: Elihu H. Estey, Peter F. Thall, Miloslav Beran, Hagop M. Kantarjian, Sherry Pierce, Michael J. Keating - Blood 1997 cited by 236

  16. Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib

    Authors: Patricia Ault, Hagop M. Kantarjian, Susan O’Brien, Stefan Faderl, Miloslav Beran, Mary Beth Rios, Charles Koller, Francis J. Giles, Michael J. Keating, Moshe Talpaz, Jörge E. Cortes - Journal of Clinical Oncology 2006 cited by 232

  17. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells

    Authors: Rui Zheng, Mark J. Levis, Obdulio Piloto, Patrick A. Brown, Brenda R. Baldwin, Norbert Claude Gorin, Miloslav Beran, Zhenping Zhu, Dale L. Ludwig, Dan Hicklin, Larry Witte, Yiwen Li, Donald Small - Blood 2003 cited by 203

  18. AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

    Authors: Mirna Golemović, Srđan Verstovšek, Francis J. Giles, Jörge E. Cortes, Taghi Manshouri, Paul W. Manley, Jürgen Mestan, Margaret Dugan, Leila Alland, James D. Griffin, Ralph B. Arlinghaus, Tong Sun, Hagop M. Kantarjian, Miloslav Beran - Clinical Cancer Research 2005 cited by 202

  19. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

    Authors: Susan O’Brien, Hagop M. Kantarjian, M Keating, Miloslav Beran, Charles Koller, L. E. Robertson, J Hester, MB Rios, M. Andreeff, Moshe Talpaz - Blood 1995 cited by 182

  20. Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia

    Authors: Elihu H. Estey, Francis J. Giles, Miloslav Beran, Susan O’Brien, Sherry Pierce, Stefan Faderl, Jörge E. Cortes, Hagop M. Kantarjian - Blood 2002 cited by 176

  21. PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders

    Authors: Elias Jabbour, Hagop M. Kantarjian, Jörge E. Cortes, Deborah A. Thomas, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Stefan Faderl, Mary Ann Richie, Miloslav Beran, Francis J. Giles, Srđan Verstovšek - Cancer 2007 cited by 113

  22. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia

    Authors: Francesco Onida, Greg Ball, Hagop M. Kantarjian, Terry L. Smith, Armand B. Glassman, Maher Albitar, Barbara Scappini, Mary Beth Rios, Michael J. Keating, Miloslav Beran - Cancer 2002 cited by 101

  23. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

    Authors: Omar Abdel‐Wahab, Animesh Pardanani, Jay Patel, Martha Wadleigh, Terra L. Lasho, Adriana Heguy, Miloslav Beran, D. Gary Gilliland, Ross L. Levine, Ayalew Tefferi - Leukemia 2011 cited by 229

  24. RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant

    Authors: Clara Ricci, Elisa Fermo, Stefania Corti, Mauro Molteni, Alessio Faricciotti, Agostino Cortelezzi, Giorgio La Nasa, Miloslav Beran, Francesco Onida - Clinical Cancer Research 2010 cited by 137